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B Clinical core needle biopsies
Supplementary Figure 1. DNA, RNA and protein yields from core needle biopsies processed
using BioTExt. A. Box plot showing DNA, RNA and Protein yields from a total of 8 core needle biopsies
from 4 PDX Models: WHIM4, 14, 18 and 20. Error bars represent standard error of mean (SEM).
B. Box and scatter plots showing DNA, RNA and protein yields from all core needle biopsies that were
processed from the DP1 study. Samples with no yield were excluded. Error bars represent standard error
of mean (SEM).
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Supplementary Figure 2. Comparison of proteomics and phosphoproteomics dataset from tumor bulk
and core samples. A. The table shows the number of proteins and phosphosites quantified in the bulk
tissue (upper panel) and non-adjacent (lower panel) cores from 4 WHIM PDX models B. The table lists
the Pearson correlation between replicate bulk and non-adjacent cores for each of the PDX models C.
Unsupervised hierarchical clustering (1-Pearson) of normalized TMT protein and phosphosite ratios. D.
ssGSEA was performed on normalized TMT protein ratios obtained from cores and bulk. Scatter plot
shows ssGSEA normalized enrichment scores (NES) between cores and bulk tissue for individual PDX
models.
Supplementary Figure 3. Reporting Recommendations for Tumor Marker Prognostic Studies
(REMARK) diagram. The flowchart shows the number of patients enrolled in the trial and reasons




Supplementary Figure 4. Proteogenomics features of the clinical cores. A. The left panel shows a
scatter plot of the percentage of target bases at 50X sequencing depth and of mean bait coverage for
whole-exome sequencing and the right panel shows comparable mean distribution of the percentage
of target bases at 50X sequencing depth for DNA isolated from blood versus that obtained from
tumor using BioTExt The error bars represent standard error of mean. B. Heatmap summarizing
genomic alterations of breast cancer associated genes in tumors from 14 patients. C. The copy
number landscape of ERBB2+ samples from TCGA (top) resembles the landscape from this study
(bottom). Plots show log2 ratios of chromosome segment copy number in tumor DNA relative to
normal DNA for each patient (rows) from each cohort. D. Distribution of gene-wise Spearman
correlations between RNA and Protein as observed using the BioTExt pipeline. Red and green
indicate all positively and negatively correlated genes respectively.
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Supplementary Figure 5. Functional prediction from co-expression networks derived from and
unsupervised hierarchical clustering of samples from clinical core proteogenomics data. A. Co-
expression networks derived from microscaled proteomics data predict function more consistently
than co-expression networks derived from the RNA data. Red and blue circles indicate functional
categories (KEGG pathways) predicted by co-expression networks derived from protein and mRNA
expression data, respectively. B. Core needle biopsies from the same patients cluster together based






Supplementary Figure 6. Validation of ERBB2 levels. A. ERBB2 (HER2) immunohistochemistry
(IHC) on sections from all 14 patients. A. Photomicrographs showing ERBB2 IHC staining
profiles of all pCR cases at 200X. Scale bar represents 200 um for all. B. Box plot showing
ERBB2 IHC scores and ERBB2 protein levels. P-value is from Wilcoxon two-sample rank sum
test comparing pre-treatment log2 TMT ratios from IHC 1+ and 2+ samples (n=5) to those from
IHC 3+ samples (n=15). C. Box plot showing ERBB2 IHC scores and ERBB2 protein levels as
measured by parallel reaction monitoring (PRM). P-value is from Wilcoxon two-sample rank sum
test comparing pre-treatment log2 PRM intensities from IHC 1+ and 2+ samples (n=5) to those
from IHC 3+ samples (n=14). D. Scatter plot showing correlation between ERBB2 protein
abundance measured using TMT and PRM based protein quantification for all cores (statistics
shown for Spearman correlation, n=32). Boxplots are centered on the median and show first and
third quartiles for each group.
Supplementary Figure 7. Scatter plots of response
to treatment (on-treatment vs pre-treatment) in non-
pCR (y-axis) vs. pCR patients for RNA (A), proteins
(B), and phosphoproteins (C) (mean of
phosphosites). Shown are log2 ratios from limma
linear modeling of differential expression for genes
with p<0.05 in each set of patients. Genes from the
ERBB signaling KEGG pathway (hsa04012) are
highlighted in orange. The level of transparency of
each point reflects it’s significance after BH-
adjustment (adjusted p<0.05 points are completely
opaque, and more transparent points have higher
adjusted p-values). n=2 for non-pCR samples
(BCN1369 excluded because patient didn’t receive
Pertuzumab) and n=7 for pCR samples (n=6 for pCR
mRNA).
Supplementary Figure 8. PTM-SEA analysis on pre and on-treatment phosphoproteomics dataset.
PTM-SEA was applied to the signed Log10 p-values from limma differential expression analysis of
on- vs. pre-treatment phosphosite levels from pCR cases (orange) and non-pCR (green) The
heatmap shows the Normalized Enrichment Scores (NES) for these kinase signatures, and asterisks
indicate significant FDR (<0.05).
Supplementary Figure 9. Outlier analysis was performed to identify differentially regulated mRNA,
proteins or phosphoproteins in each pre-treatment sample from non-pCR cases relative to the set of
pre-treatment samples from all pCR cases. Shown are the ERBB2 (HER2) RNA (A) and
phosphoprotein (B) distributions across all patients; brown and green bars indicate the frequencies for
each protein level bin in non-pCR and pCR, respectively. The line shows the normal distribution of
pCR samples from which the Z-score for each non-pCR sample was derived. Z-score thresholds are
indicated by red lines.
Supplementary Figure 10. Expression of key immune checkpoint regulators in and
immunoprofiling of pre-treated samples. Upper panel shows Z-scores of RNA, protein, and
phosphoprotein expression (where available) of key immune checkpoint inhibitors in each
baseline sample from pCR (samples on right) and non-pCR (samples on left) patients. Bottom
panel shows Z-scores of immune cell profiles inferred from RNA-seq data using Cibersort.
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Supplementary Figure 11. Hematoxylin and eosin (HE) staining of patient samples. HE staining of
tissue sections from all 14 patients and scale bar represents 100 um for all panels as shown in one
representative.. The middle panel shows magnified HE stains (400X) of sections from AR+ patients
1331 and 1371 and scale bar represents 50 um. Patient 1371 shows distinct apocrine features as
indicated by plump pink cytoplasm. The lower panel shows immunohistochemical staining profiles



























Supplementary Figure 12. Association of outliers with publications containing the keywords “breast
cancer” and “resistance” or “recur”. Z-score for each gene from outlier analysis is plotted on the y-
axis, while the x-axis indicates the number of publications associated with that gene and with breast
cancer resistance terms. A separate plot is included for outliers for each non-pCR sample from each
omics dataset.
A. B.
Supplementary Figure 13.  ERBB2 and MUCIN expression in WHIM35, WHIM8 and patient 
BCN1326. A. Heatmap showing ERBB2 pathway and Mucin protein expression in two HER2-
enriched PDX (WHIM) models with ERBB2 protein expression. B. MUC1 immunohistochemistry 
(IHC) of WHIM8, WHIM35 and BCN1369 and scale bar represents 200 um for all of B
